Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Fallopian tube cancer
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center
Results 1-25 of 92 for your search:
Start Over
Intraperitoneal and/or Intravenous Carboplatin or Cisplatin and Paclitaxel in Treating Patients With Newly Diagnosed, Stage IIB-IV Epithelial Ovarian Cancer, Peritoneal Cavity, or Fallopian Tube Cancer
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: OV.21, NCI-2013-00331, 0902, CAN-NCIC-OV21, CDR0000655241, GEICO-0902, SWOG OV.21, UCL08/0379, NCIC CTG OV.21, NCT00993655
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY005, NCI-2015-00651, NCT02502266
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients with Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: Not specified
Trial IDs: GOG-0225, NCI-2009-00595, CDR0000594600, NCT00719303
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 8109-002, NCI-2011-00940, EC-FV-06, NCT01170650
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D0818C00001, NCI-2013-01951, NCT01844986
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR100983, NCI-2013-01419, 2012-004808-34, ET743OVC3006, NCT01846611
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ARRAY-162-311, NCI-2013-00934, 2013-000277-72, NCT01849874
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D0816C00002, NCI-2014-00976, NCT01874353
Phase III Trial of Maintenance FANG™ for High Risk Stage III/IV Ovarian Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CL-PTL-119, NCI-2015-01040, NCT02346747
Olaparib or Cediranib Maleate and Olaparib Compared with Standard Platinum-Based Chemotherapy in Treating Patients with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: Not specified
Trial IDs: NRG-GY004, NCI-2015-00606, NCT02446600
Cediranib Maleate and Olaparib in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 09-293, NCI-2012-02938, DFCI IRB 09-293, NCI-2010-01329, NCI-2013-00578, NCT01115829, 8348, NCT01116648
Vaccine Therapy in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC29810, NCI-2011-00285, NCT01312389
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADP-0011-001, NCI-2015-00728, 230612, NCT01567891
A Study of LY2228820 for Recurrent Ovarian Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12517, NCI-2012-01426, I1D-MC-JIAE, NCT01663857
Paclitaxel and Vascular-Targeting Gene Therapeutic VB-111 in Treating Patients with Recurrent Uterine, Ovarian, and Fallopian Tube Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 11-418, NCI-2013-00628, NCT01801215, VB-111-157, NCT01711970
A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 21
Trial IDs: M18-005, NCI-2014-01397, NCT01952249
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GYN-064, NCI-2013-01416, 13-028, NCT01962948
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 248613, NCI-2014-00771, NCT02166905
Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: F140214007 (UAB 1357), NCI-2015-00264, 000505867, NCT02195973
A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 24360-204, NCI-2015-00040, NCT02327078
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
Start Over